Secondary analysis of the TriMaster crossover trial (309 adults with type 2 diabetes given sitagliptin, canagliflozin and pioglitazone): a routine-features prediction model beat cluster-based allocation for HbA1c reduction (0.27% vs 0.16%); DDRTree showed no association.
Secondary analysisn = 309
Güdemann et al. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial